|
|
| Line 1: |
Line 1: |
| [[Image:2cf9.gif|left|200px]] | | {{Seed}} |
| | [[Image:2cf9.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
| Line 9: |
Line 10: |
| {{STRUCTURE_2cf9| PDB=2cf9 | SCENE= }} | | {{STRUCTURE_2cf9| PDB=2cf9 | SCENE= }} |
|
| |
|
| '''THROMBIN-METHOXY2'''
| | ===THROMBIN-METHOXY2=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| Two series of tricyclic inhibitors of the serine protease thrombin, imides (+/-)-1-(+/-)-8 and lactams (+/-)-9-(+/-)-13, were analysed to evaluate contributions of orthogonal multipolar interactions with the backbone C=O moiety of Asn98 to the free enthalpy of protein-ligand complexation. The lactam derivatives are much more potent and more selective inhibitors (K(i) values between 0.065 and 0.005 microM, selectivity for thrombin over trypsin between 361- and 1609-fold) than the imide compounds (Ki values between 0.057 and 23.7 microM, selectivity for thrombin over trypsin between 3- and 67-fold). The increase in potency and selectivity is explained by the favorable occupancy of the P-pocket of thrombin by the additional isopropyl substituent in the lactam derivatives. The nature of the substituent on the benzyl ring filling the D pocket strongly influences binding potency in the imide series, with Ki values increasing in the sequence: F < OCH2O < Cl < H < OMe < OH < N(pyr)<< Br. This sequence can be explained by both steric fit and the occurrence of orthogonal multipolar interactions with the backbone C[double bond, length as m-dash]O moiety of Asn98. In contrast, the substituent on the benzyl ring hardly affects the ligand potency in the lactam series. This discrepancy was clarified by the comparison of X-ray structures solved for co-crystals of thrombin with imide and lactam ligands. Whereas the benzyl substituents in the imide inhibitors are sufficiently close (< or =3.5 Angstroms) to the C=O group of Asn98 to allow for attractive orthogonal multipolar interactions, the distances in the lactam series are too large (> or =4 Angstroms) for attractive dipolar contacts to be effective.
| | The line below this paragraph, {{ABSTRACT_PUBMED_16763681}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 16763681 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_16763681}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
| Line 39: |
Line 43: |
| [[Category: Serine protease]] | | [[Category: Serine protease]] |
| [[Category: Serine protease inhibitor complex]] | | [[Category: Serine protease inhibitor complex]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 21:59:38 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 11:10:17 2008'' |